Lansoprazole

How to order Lansoprazole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Lansoprazole on Prescriptsy

Lansoprazole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Lansoprazole is a proton pump inhibitor (PPI) widely prescribed in the United Kingdom to treat conditions caused by excess stomach acid.

It is used for gastro-oesophageal reflux disease (GORD), peptic ulcers (both gastric and duodenal), NSAID-associated gastric damage, Zollinger-Ellison syndrome, and as part of combination regimens to eradicate Helicobacter pylori infection.

Lansoprazole is available as 15 mg and 30 mg gastro-resistant capsules and orodispersible tablets.

It is classified as a prescription-only medicine at the 30 mg strength, while a 15 mg formulation is available over the counter as a pharmacy medicine for short-term self-treatment of reflux symptoms.

This page provides a comprehensive clinical overview of lansoprazole for UK patients and prescribers.

Acid-related disorders of the upper gastrointestinal tract are among the most common reasons for GP consultations in the United Kingdom.

GORD alone affects an estimated 10 to 20 percent of the adult population, causing symptoms such as heartburn, acid regurgitation, and chest discomfort.

Peptic ulcer disease, though less prevalent than in previous decades thanks to Helicobacter pylori eradication programmes and reduced NSAID prescribing, remains clinically significant.

Proton pump inhibitors revolutionised the treatment of these conditions when they were introduced in the late 1980s and early 1990s, and they remain the most effective class of acid-suppressing drugs available today.

Important safety information about lansoprazole

Before reading further, note these essential safety points about lansoprazole.

• Lansoprazole should not be used to treat uninvestigated alarm symptoms such as unintentional weight loss, difficulty swallowing, persistent vomiting, vomiting blood, or black tarry stools. These require urgent assessment.
• Use the lowest effective dose for the shortest necessary duration. Long-term use should be regularly reviewed.
• Long-term PPI therapy may cause low magnesium, reduced calcium and vitamin B12 absorption, and increased susceptibility to gut infections.
• Lansoprazole interacts with several medicines, including clopidogrel and methotrexate. Inform your prescriber of all medicines you take.
• Lansoprazole can mask the symptoms of gastric cancer. Ensure appropriate investigation before starting treatment in patients with alarm features.

Understanding acid-related conditions

The stomach normally produces hydrochloric acid, secreted by parietal cells in the gastric mucosa.

This acid is essential for activating pepsinogen into pepsin (which digests proteins), destroying ingested bacteria, and facilitating the absorption of certain nutrients including iron, calcium, and vitamin B12.

The stomach lining is protected from its own acid by a layer of mucus and bicarbonate, along with tight cellular junctions and rapid epithelial turnover.

When this protective barrier is disrupted, or when acid is produced in excess, damage to the gastric or duodenal mucosa can result.

Gastro-oesophageal reflux disease occurs when gastric contents, including acid and pepsin, reflux into the oesophagus, which lacks the robust mucosal defences of the stomach.

The lower oesophageal sphincter normally prevents reflux, but weakness, transient relaxation, or increased intra-abdominal pressure (as in obesity or pregnancy) can allow acid to escape into the oesophagus, causing heartburn, regurgitation, and, over time, oesophageal inflammation (oesophagitis).

Untreated, chronic GORD can lead to stricture formation, Barrett's oesophagus (a premalignant condition), and, rarely, oesophageal adenocarcinoma.

Peptic ulcer disease includes gastric ulcers (in the stomach) and duodenal ulcers (in the first part of the small intestine).

The two main causes are infection with Helicobacter pylori and the use of nonsteroidal anti-inflammatory drugs (NSAIDs). H.

pylori colonises the gastric mucosa and disrupts the mucosal defence mechanisms, while NSAIDs inhibit prostaglandin synthesis, reducing mucosal blood flow and bicarbonate secretion.

Peptic ulcers can cause epigastric pain, bloating, nausea, and, if they erode into blood vessels, gastrointestinal bleeding.

How lansoprazole works: mechanism of action

Lansoprazole belongs to the class of substituted benzimidazole proton pump inhibitors, which also includes omeprazole, esomeprazole, pantoprazole, and rabeprazole.

After oral administration, lansoprazole is absorbed in the small intestine (the gastro-resistant formulation protects it from destruction by stomach acid) and enters the systemic circulation.

It is a prodrug that is converted to its active form in the highly acidic environment (pH below 2) of the secretory canaliculi of parietal cells.

The active form binds covalently to cysteine residues on the hydrogen-potassium ATPase (proton pump) enzyme, irreversibly inactivating it.

Because the inactivation is irreversible, acid secretion only resumes when new proton pump molecules are synthesised and inserted into the parietal cell membrane, a process that takes approximately 3 to 5 days.

This explains why the full acid-suppressing effect of lansoprazole takes several days to develop and why acid suppression persists for some time after the drug is discontinued.

A single 30 mg dose reduces intragastric acidity by approximately 80 to 90 percent over 24 hours.

Steady-state maximal acid suppression is typically achieved after 3 to 5 days of daily dosing.

Compared with H2 receptor antagonists (such as ranitidine, which has been withdrawn, and famotidine), PPIs produce more complete and sustained acid suppression because they block the final common pathway of acid secretion regardless of the stimulus (histamine, acetylcholine, or gastrin).

This makes them the drugs of choice for conditions requiring profound acid suppression, such as erosive oesophagitis, peptic ulcer healing, and H. pylori eradication.

Clinical evidence and UK prescribing guidance

Lansoprazole has a robust evidence base supporting its efficacy in acid-related disorders.

Randomised controlled trials have demonstrated healing rates of over 90 percent for duodenal ulcers at 4 weeks and over 85 percent for gastric ulcers at 8 weeks.

In GORD, lansoprazole 30 mg daily heals erosive oesophagitis in approximately 85 to 90 percent of patients after 8 weeks. For H.

pylori eradication, triple therapy combining lansoprazole with two antibiotics achieves eradication rates of 80 to 90 percent, though resistance to clarithromycin is an emerging concern that may reduce effectiveness in some populations.

NICE clinical knowledge summaries recommend PPIs as first-line pharmacological treatment for GORD that does not respond to lifestyle modifications, for healing peptic ulcers, and as part of H.

pylori eradication regimens.

The BNF lists lansoprazole alongside omeprazole, esomeprazole, pantoprazole, and rabeprazole, noting that there is no consistent evidence that one PPI is more effective than another at equivalent doses.

The choice between them is often based on cost, formulation preference, and interaction profile.

Lansoprazole orodispersible tablets are useful for patients who have difficulty swallowing capsules or who require administration via a nasogastric tube.

NHS medicines optimisation guidance emphasises reviewing PPI prescriptions regularly.

Deprescribing PPIs in appropriate patients (those without ongoing indications such as Barrett's oesophagus, severe oesophagitis, or chronic NSAID use with high bleeding risk) is encouraged to reduce unnecessary long-term use and its associated risks.

Lansoprazole compared with other PPIs and acid-suppressing treatments

All PPIs share the same mechanism of action and produce similar levels of acid suppression at therapeutic doses.

Omeprazole is the most widely prescribed PPI worldwide and has the longest track record.

Esomeprazole, the S-enantiomer of omeprazole, is marketed as having slightly more predictable pharmacokinetics due to lower dependence on CYP2C19 metabolism, though the clinical significance of this difference is debated.

Pantoprazole has fewer drug interactions than lansoprazole and omeprazole, making it potentially preferable in patients on complex medication regimens.

Rabeprazole has a non-enzymatic activation step that may give it a slightly faster onset of action.

Lansoprazole is distinguished by the availability of an orodispersible tablet formulation, its relatively rapid onset of acid suppression (often producing symptom relief within 24 hours), and its competitive cost as a generic.

In clinical practice, switching between PPIs is common when a patient does not respond adequately to the initial choice, though systematic review evidence suggests that response rates are broadly comparable across the class.

H2 receptor antagonists (currently famotidine and cimetidine in the UK, following the withdrawal of ranitidine over NDMA contamination concerns) are less potent acid suppressants than PPIs but remain useful for mild, intermittent symptoms and as adjunctive therapy.

Antacids (aluminium and magnesium salts) and alginates (such as Gaviscon) provide rapid but short-lived symptom relief and are appropriate for occasional use.

Dosage and administration

Take lansoprazole once daily in the morning, at least 30 minutes before breakfast.

This timing optimises acid suppression because proton pumps are most active after fasting and are stimulated by the first meal of the day.

Swallow gastro-resistant capsules whole with water; do not crush or chew them. Orodispersible tablets should be placed on the tongue, allowed to disperse, and swallowed.

They can also be dispersed in water for administration via a nasogastric tube.

For GORD, the usual treatment course is 30 mg daily for 4 to 8 weeks, followed by a maintenance dose of 15 mg daily if needed.

For uncomplicated duodenal ulcer, 30 mg daily for 2 to 4 weeks is typical. Gastric ulcers require 30 mg daily for 4 to 8 weeks. For H.

pylori eradication, lansoprazole 30 mg twice daily is combined with antibiotics for 7 days. The dose in Zollinger-Ellison syndrome is individually adjusted, starting at 60 mg daily.

Side effects of lansoprazole

Short-term side effects

The most commonly reported side effects are headache, abdominal pain, diarrhoea, constipation, nausea, flatulence, and dizziness. These typically resolve without intervention. Dry mouth and taste disturbances occur less frequently.

Effects of long-term use

Hypomagnesaemia is a recognised risk of prolonged PPI therapy, highlighted by MHRA Drug Safety Updates. Symptoms include fatigue, muscle cramps, tremor, palpitations, and, in severe cases, seizures.

Magnesium levels should be checked before starting long-term PPI therapy and monitored periodically.

Reduced gastric acid impairs calcium absorption, and observational studies have reported a modest increase in the risk of osteoporotic fractures with long-term, high-dose PPI use, particularly in the elderly.

Vitamin B12 deficiency may develop with sustained acid suppression, as gastric acid is required to release B12 from dietary protein.

An increased risk of Clostridioides difficile infection has been associated with PPI use, as the loss of the gastric acid barrier facilitates colonisation by ingested pathogens.

Fundic gland polyps, which are benign, may develop during prolonged PPI use and are usually discovered incidentally at endoscopy.

Rare and serious side effects

Interstitial nephritis (kidney inflammation) is a rare but serious complication of PPI use.

Subacute cutaneous lupus erythematosus (SCLE) has been reported; if skin lesions develop, particularly in sun-exposed areas, seek medical advice.

Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) are very rare. Hepatic reactions, pancreatitis, and blood dyscrasias (thrombocytopaenia, leucopaenia, agranulocytosis) have also been reported rarely.

When to seek urgent medical advice

Contact your GP or call NHS 111 if you experience persistent diarrhoea (particularly after antibiotic use), muscle cramps, severe skin rash, or new joint pain.

Call 999 or attend A&E if you develop signs of a severe allergic reaction (swelling of the face, throat, or tongue; difficulty breathing), vomit blood, or pass black tarry stools.

Report any suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Alarm symptoms

Do not use lansoprazole to treat uninvestigated alarm symptoms.

Unintentional weight loss, progressive dysphagia, odynophagia (painful swallowing), persistent vomiting, haematemesis, melaena, iron-deficiency anaemia, and epigastric mass all require urgent investigation, usually with upper GI endoscopy, before starting acid-suppressing therapy.

PPI treatment can mask the symptoms of gastric cancer and delay diagnosis.

Drug interactions

Lansoprazole should not be co-administered with atazanavir, as PPI-induced acid suppression substantially reduces its absorption.

Caution is advised with clopidogrel, as PPIs may reduce its antiplatelet effect (lansoprazole appears to have a lesser interaction than omeprazole, but awareness is still needed).

Methotrexate levels may be elevated during concurrent PPI use, particularly at high doses, and temporary PPI discontinuation should be considered during high-dose methotrexate courses.

Monitor levels of theophylline, digoxin, and warfarin when starting or stopping lansoprazole.

Pregnancy and breastfeeding

Limited human data are available on the safety of lansoprazole in pregnancy. It should be used only if the expected benefit outweighs the potential risk.

Omeprazole has more extensive safety data in pregnancy and may be preferred if a PPI is required.

Lansoprazole passes into breast milk, and a clinical decision must balance the benefit of breastfeeding against the benefit of treatment.

How to get lansoprazole in the UK

Lansoprazole 30 mg is a prescription-only medicine available through the NHS.

Your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC) can prescribe it after an appropriate clinical assessment.

Lansoprazole 15 mg is available as a pharmacy (P) medicine for short-term purchase without a prescription from a pharmacist.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic lansoprazole is widely available and inexpensive.

Lifestyle advice for acid-related conditions

Medication works best alongside lifestyle modifications. Avoid eating large meals close to bedtime; leave at least 3 hours between your last meal and lying down.

Elevate the head of your bed by 10 to 15 cm if night-time reflux is a problem.

Reduce or avoid common triggers including spicy foods, fatty foods, chocolate, coffee, carbonated drinks, alcohol, and citrus.

Maintain a healthy weight, as excess abdominal fat increases intra-abdominal pressure and worsens reflux. Stop smoking, as tobacco relaxes the lower oesophageal sphincter.

Wear loose-fitting clothes around the waist. If NSAID use is contributing to your symptoms, discuss alternatives (such as paracetamol or topical preparations) with your prescriber.

Sources

• Lansoprazole 30 mg Gastro-resistant Capsules, Summary of Product Characteristics (EMC)
• Lansoprazole, British National Formulary (BNF)
• NICE CKS: GORD in adults
• Lansoprazole, NHS medicines information
• Heartburn and acid reflux, NHS
• MHRA Yellow Card Scheme